Literature DB >> 32011077

Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents.

Ourania Nicolatou-Galitis1, Erofili Papadopoulou1, Emmanouil Vardas1, Maria Kouri1, Dimitra Galiti2, Evangelos Galitis3, Konstantina-Eleni Alexiou2, Kostas Tsiklakis2, Alexandros Ardavanis4, Evangelia Razis5, Ilias Athanasiadis6, Stavroula Droufakou7, Amanda Psyrri8, Michalis V Karamouzis9, Helena Linardou10, Danai Daliani11, Dimitrios Tzanninis12, Sotirios Sachanas13, Konstantinos Laschos14, Marie-Christine Kyrtsonis15, Fotini Antoniou16, Apostolos Laskarakis17, Styllianos Giassas18, Adamantia Nikolaidi6, George Rigakos5, Anna Ntokou4, Cesar A Migliorati19, Carla I Ripamonti20.   

Abstract

OBJECTIVE: We reported the alveolar bone histology prior to dental extractions in cancer patients, who received bone-targeting agents (BTA). SUBJECTS AND METHODS: Fifty-four patients were included. Patients underwent extractions, and bone biopsies were taken.
RESULTS: Extractions were performed due to pain, swelling, purulence, fistula, and numbness, not responding to treatment, in 40 patients (group A); extractions due to asymptomatic, non-restorable teeth, were performed in 14 patients (group B). Complete alveolar jaw bone histological necrosis was observed in 28 of 40 (70%) patients of group A and none of group B (p < .001). The development of clinical osteonecrosis (MRON) was assessed in 44 patients; 10 patients, who were also treated with Low Level Laser Treatments-LLLT, were excluded from this analysis, as the alternative therapies were a confounding factor. Twelve patients, with alveolar bone histological necrosis prior to extraction, developed medication-related osteonecrosis of the jaw (MRONJ) compared with two patients with vital or mixed vital/non-vital bone (p < .0007). BTAs >1 year and concurrent targeted therapy were also significantly associated with MRONJ (p = .016 and p = .050).
CONCLUSION: Pain, swelling, purulence, fistula, and numbness were significantly associated with complete bone histological necrosis prior to extractions and increased MRONJ development. Research is justified to explore whether histological necrosis represents an early stage of osteonecrosis.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. All rights reserved.

Entities:  

Keywords:  bone necrosis; cancer; dental extraction; dental/periodontal infection; histology; osteonecrosis of the jaw

Mesh:

Substances:

Year:  2020        PMID: 32011077     DOI: 10.1111/odi.13294

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  8 in total

1.  Oral health condition in cancer patients under bisphosphonate therapy.

Authors:  Rogério Jardim Caldas; Héliton Spíndola Antunes; Camila de Oliveira Rodini Pegoraro; Fábio Ribeiro Guedes; Paulo Sérgio da Silva Santos
Journal:  Support Care Cancer       Date:  2021-06-18       Impact factor: 3.603

2.  Serum biomarkers for bisphosphonate-related osteonecrosis of the jaw: a prospective clinical study.

Authors:  Jung-Hyun Park; Sura Cho; Sun-Jong Kim; Tae-Dong Jeong; Yeung-Chul Mun; Jin-Woo Kim
Journal:  Osteoporos Int       Date:  2021-09-02       Impact factor: 5.071

Review 3.  The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists.

Authors:  Rodolfo Mauceri; Rita Coniglio; Antonia Abbinante; Paola Carcieri; Domenico Tomassi; Vera Panzarella; Olga Di Fede; Francesco Bertoldo; Vittorio Fusco; Alberto Bedogni; Giuseppina Campisi
Journal:  Support Care Cancer       Date:  2022-03-16       Impact factor: 3.359

4.  A critical assessment of the medication-related osteonecrosis of the jaw classification in stage I patients: a retrospective analysis.

Authors:  Oliver Ristow; Lena Hürtgen; Julius Moratin; Maximilian Smielowski; Christian Freudlsperger; Michael Engel; Jürgen Hoffmann; Thomas Rückschloß
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2021-04-30

5.  Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score-matched analysis.

Authors:  Hiroaki Ikesue; Kohei Doi; Mayu Morimoto; Masaki Hirabatake; Nobuyuki Muroi; Shinsuke Yamamoto; Toshihiko Takenobu; Tohru Hashida
Journal:  Support Care Cancer       Date:  2021-11-05       Impact factor: 3.603

6.  Medication Related Osteonecrosis of the Jaw: 2021 Position Statement of the Korean Society for Bone and Mineral Research and the Korean Association of Oral and Maxillofacial Surgeons.

Authors:  Jin-Woo Kim; Mi Kyung Kwak; Jeong Joon Han; Sung-Tak Lee; Ha Young Kim; Se Hwa Kim; Junho Jung; Jeong Keun Lee; Young-Kyun Lee; Yong-Dae Kwon; Deog-Yoon Kim
Journal:  J Bone Metab       Date:  2021-11-30

7.  Radiographic predictors for MRONJ in oncologic patients undergoing tooth extraction.

Authors:  Catalina Moreno-Rabié; Laurence Lapauw; Hugo Gaêta-Araujo; André Ferreira-Leite; Wim Coucke; Tim van den Wyngaert; Reinhilde Jacobs
Journal:  Sci Rep       Date:  2022-07-04       Impact factor: 4.996

Review 8.  [Management of medication-related osteonecrosis of the jaw-a review of recent study results in comparison to established strategies].

Authors:  Matthias Tröltzsch; Markus Tröltzsch; Christoph Pautke; Sven Otto
Journal:  HNO       Date:  2022-01-20       Impact factor: 1.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.